Therefore, DJ34-based treatments may show clinical efficacy toward a broad range of c-Myc–addicted cancers, including cancers driven by oncogenic c-Myc mutants, such as the c-Myc-T58 and c-Myc-P57 mutations that are often found in Burkitt's lymphoma and which are refractory to phosphoregulation (48). This evidence concerns the gene MYC and Burkitt lymphoma.